Inclusion Criteria: - Age >=18 years - Karnofsky Performance Status (KPS) >=70% - Histologic evidence of multiple myeloma, relapsed or relapsed/refractory disease for which no other approved treatment is available and clinically indicated - Adverse Events resulting from prior chemotherapy, surgery, or radiotherapy, must have resolved to acceptable grades - Adequate bone marrow, renal, adrenal, pancreatic and liver function - Hemoglobin >= 8 g/dL - Absolute neutrophil count >= 1.5 x 10^9 /L - Platelet count >= 75 x 10^9 /L (without transfusions) - Signed informed consent Exclusion Criteria: - Administration of chemotherapy, radiation, biological, immunotherapy or investigational agent within 28 days (6 weeks for nitrosourea and 12 weeks for BMT) - Patients may be receiving steroids or bisphosphonates, but doses must be stable - Patients must be off intrathecal therapy for at least 3 months prior to dosing - Ongoing coagulopathies and/or taking anticoagulants - Patients with evidence of mucosal or internal bleeding and/or platelet refractory - Significant cardiac disease - Patients with a prior hypersensitivity reaction of CTCAE Grade >= 3 to therapy containing propylene glycol or ethanol. - Pregnant or breast-feeding women - Significant bacterial, viral or fungal infection - Any other medical conditions that would impose excessive risk to the patient